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httpcense.Abstract Introduction: Spontaneous pneumothorax is classiﬁed as either primary or secondary,
recurrent pneumothorax may require further corrective and/or preventive measures such as pleu-
rodesis.
Aim of the work: The aim of this work was to compare the effectiveness of chemical pleurodesis
using iodopovidone and mechanical pleurodesis by thoracoscopic pleural abrasions in management
of recurrent spontaneous pneumothorax.
Patients and methods: Thirty patients with documented recurrent spontaneous pneumothorax
were enrolled in this study after obtaining informed consents. The patients were divided into two
groups each contains 15 patients. All patients were subjected to the following: full history taking,
thorough clinical examination, laboratory investigations including prothrombin activity and
INR, radiological evaluation and thoracoscopic intervention was done using rigid thoracoscope
and videoscopy unit.
Results: The success rate of iodopovidone pleurodesis in this study ranged from 88.7% after
1 week to 92.3% after 1 month. Whereas, the success rate of mechanical pleurodesis ranged from
73.3% after 1 week to 90.9% after 1 month. There was no signiﬁcant statistical difference between
the results of the follow up between the 2 groups after 1, 7, 30 and 90 days.
Conclusion: Chemical pleurodesis using iodopovidone was as effective as mechanical pleurodesis
by thoracoscopic pleural abrasions in management of recurrent spontaneous pneumothorax.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.24474317.
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Spontaneous pneumothorax is usually due to rupture of a
small subpleural bleb into the pleural cavity and affects mainly
young men. After simple drainage, recurrence occurs in about
50% of cases. The risk of recurrence increases after each new
pneumothorax. Secondary pneumothorax complicates an
underlying pulmonary disease, especially chronic obstructive
pulmonary disease with emphysema. A new form of secondaryis. Production and hosting by Elsevier B.V.
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mune deﬁciency syndrome (AIDS) patients with pneumocystis
carinii pneumonia [1].
Spontaneous pneumothorax is classiﬁed as either primary
or secondary. Primary spontaneous pneumothorax is associ-
ated with subpleural bullous changes and occurs predomi-
nantly between the ages of 20 and 40 years [2].
Secondary spontaneous pneumothorax occurs as a compli-
cation of intrathoracic disease. This complication typically pre-
sents after the fourth decade of life. Secondary pneumothorax
may develop spontaneously with diseases such as emphysema,
chronic bronchitis, pulmonary ﬁbrosis, and malignancy. Spon-
taneous pneumothorax due to malignancy has been reported in
patients with sarcoma, lung cancer, germ cell tumors, Hodg-
kin’s lymphoma, and non-Hodgkin’s lymphoma [1–3].
Recurrent pneumothorax may require further corrective
and/or preventive measures such as pleurodesis. If the pneu-
mothorax is the result of bullae, then bullaectomy (the removal
or stapling of bullae or other faults in the lung) is preferred [1].
Pleurodesis is the injection of a chemical irritant that trig-
gers an inﬂammatory reaction, leading to adhesion of the lung
to the parietal pleura. Substances used for pleurodesis include
talc, blood, iodopovidone and bleomycin. In addition, tho-
racoscopic mechanical pleurodesis in the form of pleural abra-
sions can be performed [4–7].
The ipsilateral recurrence rate after primary spontaneous
pneumothorax ranges from 30% after a ﬁrst attack to 80%
after a second attack, indicating the need for preventive mea-
sures to guard against recurrence. This can be achieved with
pleurodesis [8,9].
Pleurodesis was ﬁrst reported at the beginning of the 20th
century [10] and over the last 100 years, a wide variety of
agents has been used for the procedure. In the recent past,
iodopovidone has been found to be a very effective and accept-
able agent for pleurodesis. The effectiveness of iodopovidone
in pleurodesis has already been demonstrated by various stud-
ies from across the world [11–15].Aim of the work
The aim of this work was to compare the effectiveness of
chemical pleurodesis using iodopovidone and mechanical pleu-
rodesis by thoracoscopic pleural abrasions in management of
recurrent spontaneous pneumothorax.Subjects and methods
Study population and subjects
Thirty patients with documented recurrent spontaneous pneu-
mothorax, admitted to the chest department, Alexandria Uni-
versity hospital were enrolled after obtaining informed
consents. All patients had a prothrombin activity >70%.
Study measurements
The patients were divided into two groups each contains 15 pa-
tients. All patients were subjected to the following:
 Full history taking including age, sex, smoking index and
history of other diseases. Thorough clinical examination including: general examina-
tion and local chest examination.
 Laboratory investigations including prothrombin activity
and INR.
 Radiological evaluation was carried out by:
 Plain X-ray chest postero-anterior and lateral views.
 Computed tomographic (CT) scan of the chest with focus
made on the side and amount of peumothorax, pleural
lesions, underlying lung lesions, metastasis and any other
lesions that could be detected.
Thoracoscopic procedure
Thoracoscopic examination was done using rigid thoracoscope
and videoscopy unit (camera [KARL STORZ ENDOSKOPE
TELECAM PAL 20211020], light source [HENKE-SASS
WOLF GMBH D-7200 TUTTINGEN)], video recorder and
television.
The procedure was done in an especially equipped proce-
dure room in chest department, Alexandria University.
Each patient was positioned lying down in a lateral decubi-
tus position with the involved side facing upwards and graded
doses of midazolam 15 mg diluted in 15 cc normal saline was
given to the patient. The entire lateral chest wall was scrubed
with iodopovidore. After raising a 2 cm subcutaneous wheal
and anaesthetizing the skin, subcutaneous tissues, muscle
planes, rib periosteum and parietal pleura by about 20 cc of
1% lidocaine a 2 cm transverse skin incision was made by a
scalpel parallel to the rib along the intercostal space chosen
for tube insertion in the wheal. Blunt dissection of the intercos-
tal tissues was performed by spreading straight Kelly clamp
both parallel and perpendicular to the underlying muscles,
which were separated, and the parietal pleura was gently pal-
pated by the index ﬁnger and was penetrated by the Kelly
clamp. The trocar and cannula was grasped and inserted
through the incision, down the preformed tract, penetrating
the pleural membrane into the pleural cavity.
Once in place, the cannula was removed and the rigid tho-
racoscope, connected to a video camera in order to display the
whole procedure on a monitor and can be recorded on a video
tape by a video recorder, was introduced through the trocar.
Inspection of the pleural cavity was then done by the rigid
thoracoscope. The parietal pleura including the costal, dia-
phragmatic sometimes mediastinal pleura as well as the vis-
ceral pleura were thoroughly examined for any lesions such
as nodules, plaques, adhesions, thickening, mottling or anthra-
cosis. Multiple forceps biopsies were taken from any suspi-
cious gross pathological lesion in the parietal pleura. The
visceral pleura was not biopsied. The biopsies were then sent
for histopathological diagnosis. Then a suction catheter con-
nected to thoracic drainage device [HOSPIVAC sm350
REF210358] is introduced through the cannula to induce lung
expansion.
Twenty cubic centimeter of lidocaine (1% concentration)
were instilled into the pleural cavity through the chest tube
to anaesthesize the pleura. Under strict aseptic technique, 50 cm3
of iodopovidone (10% concentration) was added to 50 cm3 normal
saline in a sterile bowl and aspirated into the 50 cm3 Tommy’s syr-
inge. The syringe was attached to the rigid cannula and the solution
was instilled into the pleural cavity, then the remaining 50 cm3 of
the solution was instilled in the same manner in the ﬁrst 15 patients
Table 1 Comparison between the two studied groups accord-
ing to demographic data, symptoms and radiological ﬁndings.
Iodopovidone Mechanical abrasions p
Sex
Male 12 (80.0%) 9 (60.0%) 0.427
Female 3 (20.0%) 6 (40.0%)
Age 44.80 ± 12.17 43.67 ± 10.47 0.787
Dyspnea 15(100.0%) 15(100.0%) –
Chest pain 15(100.0%) 15(100.0%) –
Radiological ﬁndings
Right pneumothorax 9(60.0%) 7(46.7%) 0.715
Left pneumothorax 6(40.0%) 8(53.3%)
Data are expressed in numbers (%) or mean ± SD.
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sions in the parietal pleura using rough brush forceps in the other
15 patients (group II).
Then a suction catheter connected to thoracic drainage de-
vice [HOSPIVAC sm350 REF210358] was introduced through
the cannula to induce lung expansion.
After the procedure, a clamped chest tube was connected to
the suction tube of the drainage device and ﬁxed in position to
the skin of the chest wall using zero silk interrupted vertical
mattress sutures. Well-cared dressing was applied. The
dressing was routinely changed and inspected daily.
Chest radiograph was done daily to assure full lung
re-expansion. Once this latter was achieved, the chest tube
was removed. After removing the chest tube, a plain chest
radiograph was obtained.
Follow up plain X-rays chest PA view were performed 1730
and 90 days after the procedure to assess initial, early and late
success of pleurodesis.
Results
This study included thirty patients. They were divided into
two groups each contains 15 patients. Table 1 demonstrated
comparison between the two studied groups according to
demographic data, symptoms and radiological ﬁndings as
regarding sex, in the ﬁrst group 12 (80.0%) were males and
3 (20.0%) were females while in the second group 9
(60.0%) were males and 6 (40.0%) were females, with no sig-
niﬁcant statistical difference between the two groups
(p= 0.427). The mean age in the ﬁrst group was
44.80 ± 12.17 years and 43.67 ± 10.47 years in the second
group, with no signiﬁcant statistical difference between the
two groups (p= 0.787). As regarding symptoms, dyspnea
and chest pain were found in all patients of the two studied
groups. As regarding the radiological ﬁndings, right sided
pneumothorax was detected in 9 (60.0%) patients of the ﬁrst
group and in 7 (46.7%) patients of the second group.
Whereas, left sided pneumothorax was detected in 6
(40.0%) patients of the ﬁrst group and in 8 (53.3%) patients
of the second group, with no signiﬁcant statistical difference
between the two groups (p= 0.715) Fig. 1.
Table 2 and Fig. 2 demonstrated the follow up ﬁndings of
the two groups, after 1 day, in the ﬁrst group; full lung expan-
sion was detected in 14 (93.3%) cases, while persistent
pneumothorax was detected in 1 (6.7%) case. After 7 days,
full lung expansion was detected in 13 (86.7%) cases, while
persistent pneumothorax was detected in 1 (6.7%) case
and recurrent pneumothorax was detected in 1 (6.7%) case.
After 30 days, full lung expansion was maintained in 12
(92.3%) cases, while recurrent pneumothorax occurred in
only 1 (7.7%) case. Follow up after 3 months revealed
that, full lung expansion was maintained in the 12 (100%)
cases.
Whereas, in the second group, full lung expansion was de-
tected in 12 (80.0%) cases, while persistent pneumothorax was
detected in 3 (20.0%) cases. After 7 days, full lung expansion
was detected in 11(73.3%) cases, while persistent pneumotho-
rax was detected in 3 (20%) cases and recurrent pneumothorax
was detected in 1 (6.7%) case. After 30 days, out of 11 cases,
full lung expansion was maintained in 10 (90.9%) cases, while
recurrent pneumothorax occurred in only 1 (9.1%) case.Follow up after 3 months revealed that, full lung expansion
was maintained in the 10 (100%) cases.
There was no signiﬁcant statistical difference between the
results of the follow up between the two groups after 1730
and 90 days.
Discussion
The exact mechanism of pleurodesis by a sclerosing agent is
not completely understood. However, it has been shown that
the initial events that take place after the intrapleural adminis-
tration of a sclerosing agent include the denudation of meso-
thelial cells and the subsequent development of an exudative
pleural effusion [16,17]. Thereafter, the complex sequence of
events that take place include an acute inﬂammatory response
to the local injury, followed by the regeneration of the dam-
aged cells, and the wound strength is established by the migra-
tion of connective tissue cells, the synthesis of extracellular
matrix proteins and ﬁnally, collagenisation [18].
The success rate of iodopovidone pleurodesis in this study
ranged from 88.7% after 1 week to 92.3% after 1 month,
which is almost similar to the efﬁcacy of talc pleurodesis,
and other inexpensive agents used for chemical pleurodesis,
which include silver nitrate and quinacrine 32. Importantly,
iodopovidone is not only inexpensive, but is also associated
with minimal side effects [11,19,20].
The efﬁcacy of pleurodesis with iodopovidone without any
signiﬁcant adverse effects was 91.6% in a study conducted by
Morales-Gomez et al. [12] and 64.2% in a study conducted by
Kelly-Garcia et al. [13]. In both these series, pleurodesis was
performed through tube thoracostomy, iodopovidone proved
to be an extremely effective and safe agent for their pleurode-
sis. The efﬁcacy of iodopovidone is at par with that of talc, but
there is no fear of severe complications, such as acute respira-
tory distress syndrome, which occurs especially if the talc used
has a smaller particle size (<15 lm).
Moreover, pleurodesis with iodopovidone can be per-
formed under local anaesthesia with excellent tolerance and
acceptability [18].
In a study by Dey et al. [21], who said that some difﬁculty
was experienced in the form of increased resistance while inject-
ing the total volume of ﬂuid 50 ml lidocaine solution and
100 ml iodopovidone solution in the patients with recurrent
pneumothorax. It is possible that patients with pneumothorax
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Figure 1 Comparison between the two studied groups according to symptoms and radiological ﬁndings.
Table 2 Comparison between the two studied groups according to follow up chest X-ray.
After 1 day After 7 days After 30 days After 3 months
Iodopovidone (n= 15) (n= 15) (n= 13/15) (n= 12/15)
Full lung expansion 14(93.3%) 13(86.7%) 12(92.3%) 12(100.0%)
Persistent pnemothorax 1(6.7%) 1(6.7%) – –
Recurrent pneumothorx – 1(6.7%) 1(7.7%) –
Mechanical abrasions (n = 15) (n = 12/15) (n = 11/15) (n = 10/15)
Full lung expansion 12(80.0%) 11(91.7%) 10(90.9%) 10(100.0%)
Persistent pnemothorax 3(20.0%) 0(0.0%) – –
Recurrent pneumothorx – 1(8.3%) 1(9.1%) –
P 0.598 1.000 1.000 –
Data are expressed in numbers (%).
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but this difﬁculty was not experienced in the present study.
The success rate of mechanical pleurodesis in this study ran-
ged from 73.3% after 7 days to 90.9% after 1 month. Similar
result was detected by Wochenschr [22], stated that thoraco-scopic mechanical pleurodesis is an effective palliative method
for the treatment of recurrent pleural effusions and recurrent
pneumothorax, with a minimum number of complications
and a short period of hospitalization. After Thoracoscopic
mechanical pleurodesis there is signiﬁcant improvement in
Chemical pleurodesis using iodopovidone versus mechanicalpleurodesis in management of recurrent pneumothorax 109respiratory functions, and for the patient it represents a rela-
tively simple surgical procedure. In addition, similar to Chen
et al. [23], who reported that pleural abrasion, is as effective
as apical pleurectomy and either technique is appropriate for
treating primary spontaneous pneumothorax patients with
high recurrence risk.
In the present study, no signiﬁcant statistical difference was
detected between the results of the follow up between the two
groups after 1730 and 90 days following iodopovidone and
mechanical pleurodesis. This was in agreement with Sepehri-
pour et al. [24], who reported that there is a very similar out-
come proﬁle in the comparison between mechanical and
chemical pleurodesis, with modest evidence suggesting lower
rates of recurrence with chemical talc pleurodesis. The reverse
was detected by Hamdy et al. [25], who reported that pleurod-
esis using minocycline instillation via thoracoscopy is more
effective than mechanical abrasions induced by brushing.
In conclusion, chemical pleurodesis using iodopovidone is as
effectiveasmechanicalpleurodesisby thoracoscopicpleural abra-
sions in management of recurrent spontaneous pneumothorax.
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